Immunodiagnostics Systems Ltd (IDS)
As a leading specialist diagnostic company, our mission is to deliver improved outcomes for patients in our selected fields of speciality. We deliver innovative and effective assays, and instruments of the highest quality. We actively encourage the discovery of novel biomarkers in our selected specialist fields, and ultimately drive towards their successful commercialisation. The strategic intent of IDS is to hold a leadership position in specialist diagnostics. Our aim is to compliment the products supplied by the main diagnostic providers rather than compete with them. We continue to dev.... Read more
The IDS-iSYS combines 50 years of instrumentation engineering experience with world-r...
As a leading specialist diagnostic company, our mission is to deliver improved outcomes for patients in our selected fields of speciality. We deliver innovative and effective assays, and instruments of the highest quality. We actively encourage the discovery of novel biomarkers in our selected specialist fields, and ultimately drive towards their successful commercialisation.
The strategic intent of IDS is to hold a leadership position in specialist diagnostics. Our aim is to compliment the products supplied by the main diagnostic providers rather than compete with them. We continue to develop and market both manual and fully automated specialist immunoassay testing solutions for both the Research and Clinical laboratory markets.
The increase in the aging population throughout the world has resulted in a higher incidence of conditions such as osteoporosis, rheumatoid and osteoarthritis, renal and cardiovascular disease. The spiralling socio-economic costs of fractures and other age-related morbidities are driving the need for better tools to monitor health and diagnose disease onset much earlier. The goal of IDS is to satisfy this need.
The strategic intent of IDS is to hold a leadership position in specialist diagnostics. Our aim is to compliment the products supplied by the main diagnostic providers rather than compete with them. We continue to develop and market both manual and fully automated specialist immunoassay testing solutions for both the Research and Clinical laboratory markets.
The increase in the aging population throughout the world has resulted in a higher incidence of conditions such as osteoporosis, rheumatoid and osteoarthritis, renal and cardiovascular disease. The spiralling socio-economic costs of fractures and other age-related morbidities are driving the need for better tools to monitor health and diagnose disease onset much earlier. The goal of IDS is to satisfy this need.